

DIVISION - CONTINUATION - CONTINUATION-IN-PART APPLICATION TRANSMITTAL FORM				Attorney Docket No.: 2959-B	
Anticipated Classification Of This Application: Class		Subclass		Prior Application: Examiner Maher M. Haddad	
				Art Unit 1644	

00743 U.S. PTO

10/648136

08/26/03

To the Commissioner for Patents:

This is a request for filing a ☐ continuation ☒ divisional ☐ continuation-in-part application, under 37 CFR 1.53(b), of pending prior application Serial No. 09/921,667 filed on August 3, 20 01, of Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy and John D. Pluenneke for METHODS FOR TREATING AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30 OR CD30L

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. ☒ Transmitted herewith are:

☒ 48 pages of specification, 4 pages of claim(s) and 1 page of abstract, **totaling** 53 pages.

☐ sheet(s) of drawings.

☒ 3 pages of Oath or Declaration by the applicant(s):

☐ a. Newly executed (original or copy)

☒ b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional applns. only)

☒ 25 pages of Sequence Listing; sequence statement.

2. ☒ The filing fee is calculated below:

For	Number Filed		Number Extra	Rate	Fee
Total Claims	28	- 20 =	8	x \$18.00 =	\$ 144.00
Independent Claims	2	- 3 =	0	x \$84.00 =	0.00
Multiple Dependent Claims	0			+ \$280.00 =	0.00
Basic Fee				\$750.00 =	750.00
Total Filing Fee					\$ 894.00

3. ☒ Please charge Deposit Account No. 09-0089, in the name of Immunex Corporation, in the amount of \$ 894.00. An original and one copy are enclosed.

4. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.

5. ☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 09-0089 throughout the prosecution of this application.

6. ☐ Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

7. ☐ Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a ☐ continuation ☐ division of application Serial No. _____, filed _____, which is/are hereby incorporated by reference.--

8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. ☐ New formal drawings are enclosed.

9. ☐ Priority of application Serial No. _____ filed on _____ in _____ (country) is claimed under 35 USC 119.

9a. ☐ The certified copy has been filed in prior application Serial No. _____ filed _____

10. ☐ The prior application is assigned of record to IMMUNEX CORPORATION
Reel 012281 Frame 0427

11. ☐ A preliminary amendment is enclosed.

12. ☒ Also enclosed Certificate of Express Mailing; Statement and Power of Attorney by Assignee with Copy of Assignment; Information Disclosure Statement; Form PTO-1449

13. ☐ Other: _____

14. ☐ The power of attorney in the prior application is to:
Customer No. 22932


a. ☒ The power appears in the original papers in the prior application.

b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

c. ☒ Address all future communications to
Patricia Anne Perkins
at the address below.

Signator: ☐ Assignee of complete interest

☒ Attorney or agent of record


Patricia Anne Perkins
Agent for Applicants
Registration No. 34,693
Phone: (206) 265-4782
Date: August 26, 2003

Please send all future correspondence to:

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
(206) 587-0430



22932

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2959-B

Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon,
Mary K. Kennedy and John D. Pluenneke

Serial No.: -- to be assigned--
(Divisional of 09/921,667)

Filing Date: August 26, 2003

For: METHODS FOR TREATING AUTOIMMUNE AND CHRONIC
INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30 AND
CD30L

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PATENT APPLICATION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL LABEL NUMBER: ET 437819810 US

I hereby certify that the following correspondence is enclosed and is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date listed below, and is addressed to Mail Stop PATENT APPLICATION, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

- Postcard
- Divisional Application Transmittal Form (2 pages + copy)
- Specification, claims and abstract (53 pgs.)
- Sequence Listing (25 pgs)
- Sequence Statement Pursuant to 37 CFR § 1.821(e)
- Declaration of Inventors (3 pgs)
- Statement Under 37 CFR 3.73(b) and Power of Attorney by Assignee and copy of Assignment (5 pgs)
- Information Disclosure Statement (2 pgs)
- Form PTO-1449 (2 pgs)

Signed: Elizabeth M. McCarthy
Elizabeth M. McCarthy

Date: August 26, 2003